NCT07244510

Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase II, Multicenter, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SCT650C in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Sinocelltech Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SCT650C in patients with Moderate to Severe Hidradenitis Suppurativa

Detailed description

This is a Phase II, multicenter, double-blinded, placebo-controlled study to evaluate the safety and efficacy of SCT650C in adult participants with Moderate to Severe Hidradenitis Suppurativa. This study includes 3 periods (Screening period, Loading period and Maintenance period ), and ≤ 60 participants in 3 groups (Group 1, 2 and 3)

Conditions

• Hidradenitis Suppurativa (HS)

Interventions

Type	Name	Description
DRUG	SCT650C	Administered SC

Timeline

• Start date: 2025-11-18
• Primary completion: 2027-03-12
• Completion: 2028-02-16
• First posted: 2025-11-24
• Last updated: 2025-11-24